AR051853A1 - Vacuna para aumentar el crecimiento basada en epitopes neutralizantes - Google Patents

Vacuna para aumentar el crecimiento basada en epitopes neutralizantes

Info

Publication number
AR051853A1
AR051853A1 ARP050105433A ARP050105433A AR051853A1 AR 051853 A1 AR051853 A1 AR 051853A1 AR P050105433 A ARP050105433 A AR P050105433A AR P050105433 A ARP050105433 A AR P050105433A AR 051853 A1 AR051853 A1 AR 051853A1
Authority
AR
Argentina
Prior art keywords
fusion protein
gdf8 peptide
plant virus
vaccine
peptide domain
Prior art date
Application number
ARP050105433A
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR051853A1 publication Critical patent/AR051853A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee una proteína de fusion que comprende una proteína de envoltura de un virus de planta y un dominio del péptido GDF8, o fragmento antigénico del dominio del péptido GDF8. También se proveen vectores de virus de plantas que expresan la proteína de fusion y métodos de uso de estos vectores. Reivindicacion 1: Una proteína de fusion que comprende: (a) un dominio del péptido GDF8, o un fragmento antigénico del dominio del péptido GDF8, donde el dominio del péptido GDF8 comprende los residuos de aminoácidos 327 a 346 de la SEC ID N°: 1; y (b) una proteína de envoltura de un virus de planta, o por lo menos un fragmento de una proteína de envoltura de un virus de planta. Reivindicacion 16: Un ácido nucleico que codifica la proteína de fusion de la reivindicacion 1. Reivindicacion 22: Una célula huésped que comprende el vector replicable de la reivindicacion 18. Reivindicacion 24: Una planta de tabaco que comprende la célula huésped de la reivindicacion 23.
ARP050105433A 2004-12-30 2005-12-21 Vacuna para aumentar el crecimiento basada en epitopes neutralizantes AR051853A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64040804P 2004-12-30 2004-12-30
US66569005P 2005-03-28 2005-03-28

Publications (1)

Publication Number Publication Date
AR051853A1 true AR051853A1 (es) 2007-02-14

Family

ID=36374780

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105433A AR051853A1 (es) 2004-12-30 2005-12-21 Vacuna para aumentar el crecimiento basada en epitopes neutralizantes

Country Status (11)

Country Link
US (2) US7432079B2 (es)
EP (1) EP1831372A2 (es)
JP (2) JP2008526201A (es)
AR (1) AR051853A1 (es)
AU (1) AU2005323087A1 (es)
CA (1) CA2594276A1 (es)
MX (1) MX2007008132A (es)
MY (1) MY144766A (es)
PE (1) PE20060860A1 (es)
TW (1) TW200634156A (es)
WO (1) WO2006073827A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004312411B8 (en) 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
TW200634156A (en) * 2004-12-30 2006-10-01 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
WO2013028330A2 (en) * 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
JP6284248B1 (ja) * 2016-11-22 2018-02-28 セイコーインスツル株式会社 電気化学セル及び電気化学セルの製造方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1192510A (en) 1981-05-27 1985-08-27 Lawrence E. Pelcher Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
WO1993008290A1 (en) 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
AU746643B2 (en) 1997-02-05 2002-05-02 Metamorphix International, Inc. Immunization against endogenous molecules
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6344597B1 (en) 1998-01-16 2002-02-05 Large Scale Biology Corporation Interspecific nicotiana hybrids and their progeny
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US6037456A (en) 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
WO1999056768A1 (en) 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
WO2000066743A2 (en) 1999-05-04 2000-11-09 Large Scale Biology Corporation Viral expression vectors
US6284882B1 (en) 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
EP1072680A1 (en) 1999-07-30 2001-01-31 Pfizer Products Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
JP3341238B2 (ja) * 1999-09-14 2002-11-05 株式会社アクーヴ・ラボ 振動を人体に感じさせる方法及びその装置
CA2385186A1 (en) * 1999-10-13 2001-04-19 Roswell Park Memorial Institute Induction of a strong immune response to a self-tumor associated antigen
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP1549140A4 (en) 2002-09-03 2009-04-29 Kentucky Bioproc Llc PRODUCTION OF PEPTIDES IN PLANTS IN THE FORM OF HYBRID VIRAL HULL PROTEINS
WO2004052930A2 (en) 2002-12-11 2004-06-24 Pharmexa A/S Targeting single epitopes
KR101304718B1 (ko) 2002-12-20 2013-09-05 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
AU2004312411B8 (en) 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
US20060281075A1 (en) * 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
TW200634156A (en) * 2004-12-30 2006-10-01 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine

Also Published As

Publication number Publication date
AU2005323087A1 (en) 2006-07-13
WO2006073827A3 (en) 2006-12-21
TW200634156A (en) 2006-10-01
CA2594276A1 (en) 2006-07-13
US20090208522A1 (en) 2009-08-20
PE20060860A1 (es) 2006-09-04
MY144766A (en) 2011-10-31
US20060159696A1 (en) 2006-07-20
WO2006073827A2 (en) 2006-07-13
EP1831372A2 (en) 2007-09-12
US7432079B2 (en) 2008-10-07
JP2008526201A (ja) 2008-07-24
MX2007008132A (es) 2007-07-20
JP2011024590A (ja) 2011-02-10

Similar Documents

Publication Publication Date Title
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
MX2021015465A (es) Vacuna para fiebre porcina africana.
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
NO20063026L (no) Antistoffer
AR047345A1 (es) Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes
MX9207113A (es) Fragmento de adn, peptido que comprende una proteina superficial ha de un virus de gripe a y vacuna que comprende tal peptido.
AR071220A1 (es) Astrovirus aviario depositado bajo el nuero cncm i-3895
AR067658A2 (es) Un polipeptido inmunogenico, un polinucleotido que lo codifica , las composiciones farmaceuticas que contienen dichos polipeptidos y polinucleotido, los vectores de xpresion, vacunas, un metodo para la preparacion de dicho polipeptido y una celula huesped aislada que expresa dicho polipeptido
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CO5580165A1 (es) Vacunas de rotavirus modificado
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
MX2022014943A (es) Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
DE60236579D1 (de) Bakteriophagenvermittelte impfung
ES2572367T3 (es) Péptidos con epítopos de la MELK y vacunas que los contienen
PE20161094A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
ATE466879T1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
AR045000A1 (es) Gen y proteina de eimeria , y su uso
ES2077017T3 (es) Vacuna contra el virus de la bronquitis infecciosa.
CO5780137A1 (es) Antigenos protectores y vacunas para el control de infestaciones por multiespecies de garrapatas